Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters
Cardiovascular disease is the leading cause of deaths in nonalcoholic steatohepatitis (NASH) patients. Mouse models, while widely used for drug development, do not fully replicate human NASH nor integrate the associated cardiac dysfunction, i.e. heart failure with preserved ejection fraction (HFpEF). To overcome these limitations, we established a nutritional hamster model developing both NASH and HFpEF. We then evaluated the effects of the dual peroxisome proliferator activated receptor alpha/delta agonist elafibranor developed for the treatment of NASH patients.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Fran çois Briand, Julie Maupoint, Emmanuel Brousseau, Natalia Breyner, Mélanie Bouchet, Clément Costard, Thierry Leste-Lasserre, Mathieu Petitjean, Li Chen, Audrey Chabrat, Virgile Richard, Rémy Burcelin, Caroline Dubroca, Thierry Sulpice Source Type: research
More News: Biomedical Science | Cardiology | Cardiovascular | Diets | Heart | Heart Failure | Men | Nutrition | Syria Health